Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial

被引：2
|
作者：
Ahn, Myung-Ju
Camidge, D. Ross
Tiseo, Marcello
Reckamp, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Langer, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William
Kerstein, David
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Univ Colorado Denver, Aurora, CO USA
[3] Univ Hosp Parma, Parma, Italy
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Odense Univ Hosp, Odense, Denmark
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[7] Univ Hosp Munich, Thorac Oncol Ctr Munich, Munich, Germany
[8] Swedish Canc Inst, Seattle, WA USA
[9] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[10] Otto Wagner Hosp, Vienna, Austria
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
[12] Yale Canc Ctr, New Haven, CT USA
[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
[14] Hosp Octubre, Dept Med Oncol, Madrid, Spain
[15] Vrije Univ VU Med Ctr, Amsterdam, Netherlands
[16] Levine Canc Inst, Charlotte, NC USA
[17] ARIAD Pharmaceut, Cambridge, MA USA
[18] Seoul Natl Univ Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20503
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK plus Non-Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial
    Kim, D.
    Tiseo, M.
    Ahn, M.
    Reckamp, K.
    Hansen, K. Holmskov
    Kim, S.
    Huber, R.
    West, H.
    Groen, H.
    Hochmair, M.
    Leighl, N.
    Gettinger, S.
    Langer, C.
    Paz-Ares Rodriguez, L.
    Smit, E.
    Reichmann, W.
    Kerstein, D.
    Haluska, F.
    Camidge, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial
    Ou, Sai-Hong Ignatius
    Tiseo, Marcella
    Camidge, D. Ross
    Ahn, Myung-Ju
    Huber, Rudolf M.
    Hochmair, Maximilian J.
    Kim, Sang-We
    West, Howard Jack
    Reckamp, Karen L.
    Molina, Julian R.
    Liu, Geoffrey
    Delmonte, Angelo
    Ramirez, Santiago Viteri
    Bearz, Alessandra
    Summers, Yvonne J.
    Reichmann, William
    Kerstein, David
    Gettinger, Scott N.
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
    Kim, Dong-Wan
    Tiseo, Marcello
    Ahn, Myung-Ju
    Reckam, Karen L.
    Hansen, Karin Holmskov
    Kim, Sang-We
    Huber, Rudolf M.
    West, Howard Jack
    Groen, Harry J. M.
    Hochmair, Maximilian J.
    Leighl, Natasha B.
    Gettinger, Scott N.
    Lange, Corey J.
    Paz-Ares, Luis G.
    Smit, Egbert F.
    Kim, Edward S.
    Reichmann, William G.
    Kerstein, David
    Haluska, Frank G.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and Phase 2 (ALTA) trials
    Huber, R.
    Gettinger, S.
    Kim, D. -W
    Bazhenova, L.
    Hansen, K.
    Tiseo, M.
    Langer, C.
    Paz-Ares Rodriguez, L.
    West, H.
    Reckamp, K.
    Weiss, G.
    Smit, E.
    Hochmair, M.
    Kim, S. -W
    Ahn, M. -J
    Kim, E.
    Groen, H.
    Pye, J.
    Vranceanu, F.
    Camidge, D. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 4 - 5
  • [5] Brigatinib (BRG) in ALK plus crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
    Gettinger, Scott N.
    Huber, Rudolf M.
    Kim, Dong-Wan
    Bazhenova, Lyudmila
    Hansen, Karin Holmskov
    Tiseo, Marcello
    Langer, Corey J.
    Paz-Ares, Luis G.
    West, Howard
    Reckamp, Karen L.
    Weiss, Glen J.
    Smit, Egbert F.
    Hochmair, Maximilian
    Kim, Sang-We
    Ahn, Myung-Ju
    Kim, Edward S.
    Groen, Harry J. M.
    Pye, Joanna
    Vranceanu, Florin
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
    Camidge, D. Ross
    Tiseo, Marcello
    Ahn, Myung-Ju
    Reckamp, Karen
    Hansen, Karin
    Kim, Sang-We
    Huber, Rudolf
    West, Howard
    Groen, Harry
    Hochmair, Maximilian
    Leighl, Natasha
    Gettinger, Scott
    Langer, Corey
    Paz-Ares, Luis
    Smit, Egbert
    Kim, Edward
    Reichmann, William
    Clackson, Tim
    Kerstein, David
    Haluska, Frank
    Kim, Dong-Wan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1169
  • [7] Brigatinib in crizotinib-refractory ALK1 NSCLC: Updates from the pivotal randomized phase 2 Trial (ALTA)
    Hochmair, M. J.
    Tiseo, M.
    Reckamp, K. L.
    West, H. L.
    Groen, H. J.
    Langer, C. J.
    Reichmann, W.
    Kerstein, D.
    Kim, D-W.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK plus NSCLC
    Yang, J. C-H.
    Liu, G.
    Lu, S.
    He, J.
    Burotto, M.
    Vincent, S.
    Yin, J.
    Ma, X.
    Popat, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1564 - S1564
  • [9] Final ALTA-1 Results of Brigatinib (BRG) and Crizotinib (CRZ) in ALK Inhibitor-naive Non-small Cell Lung Cancer (NSCLC)
    Griesinger, F.
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J
    Yang, J. C.
    Han, J. -Y
    Hochmair, M.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D. -W
    Felip, E.
    Califano, R.
    Spira, A.
    Thomas, M.
    Gettinger, S.
    Tiseo, M.
    Lin, H.
    Liu, Y.
    Zhang, P.
    Popat, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 103 - 104
  • [10] Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial
    Lee, D. H.
    Kim, D-W.
    Camidge, D. R.
    Langer, C. J.
    Huber, R. M.
    Tiseo, M.
    West, H. L.
    Groen, H. J. M.
    Reckamp, K. L.
    Hochmair, M. J.
    Leighl, N. B.
    Hansen, K. H.
    Gettinger, S. N.
    Paz-Ares, L.
    Kim, E. S.
    Smit, E. F.
    Kim, S-W.
    Ni, Q.
    Zhang, P.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2019, 30 : 634 - +
12345